Domestic Formulation Growth
12%
+12% YoY
Outpaced IPM growth of 8.9% in Q3 FY26.
IPCALABORATORIES
Diversified
12 Feb 2026
IPCA Laboratories Ltd — Q3 FY26
IPCA Laboratories delivered a solid Q3 FY26 with consolidated revenue of ₹2,245 crore (+6.5% YoY) and consolidated EBITDA margin expanding 228 bps YoY to 22.15%.
Financial stats pending filing verification
2-Minute Summary
✦ AI-Generated from Full Transcript
IPCA Laboratories delivered a solid Q3 FY26 with consolidated revenue of ₹2,245 crore (+6.5% YoY) and consolidated EBITDA margin expanding 228 bps YoY to 22.15%. Standalone EBITDA margin improved to 26.09% (+184 bps YoY). Growth was driven by strong domestic formulation performance (+12% YoY, outpacing IPM), robust export branded formulations (+17% YoY, led by West Africa +69%), and US business growth (+17% YoY). API business remained flat. Management guided for 10-12% revenue growth across segments and 150 bps annual EBITDA margin expansion, supported by product mix improvement and operating leverage. Key risks include continued market share loss at Unichem (US business) for 1-2 more quarters and pricing pressure in the UK generic market, though recent recovery is noted.
Key Numbers
US Business Revenue (Q3)
₹395 cr
+17% YoY
Consolidated US business (IPA + Unichem) grew 17% YoY in Q3.
West Africa Branded Growth
69%
+69% YoY
West Africa branded business grew 69% in Q3, driving export formulation growth.
Unichem EBITDA Margin
8%
-? bps YoY
Unichem margins under pressure due to US market share loss; expected to recover in 2-3 quarters.
Management Guidance
Revenue growth of 10-12% across segments
Management expects 10-12% growth in domestic, branded exports, and generic businesses; API slightly lower.
Management guidance growthAnnual EBITDA margin expansion of ~150 bps
At 10-11% topline growth, EBITDA margin should improve by ~1.5% per year.
Management guidance marginsUnichem to achieve 15% EBITDA margin in 2-3 years
Unichem aims for 15% EBITDA margin in 2-3 years, then gradually to 20% as European filings commercialize.
Management guidance margins5-7 new US product launches from IPA portfolio in 12-15 months
IPA will commercialize 5-7 additional molecules in the US over next 12-15 months, adding to existing 5.
Management guidance growthKey Risks
Unichem US market share loss persists
Unichem lost market share in key US products; decline may continue for 1-2 more quarters, pressuring margins.
high · management_commentaryUK generic pricing pressure
UK generic market experienced severe price erosion; though recent recovery of 30-40% seen, sustainability uncertain.
medium · management_commentaryDependence on IKA portfolio for US growth
US growth largely driven by IKA portfolio; organic IPA US business still small (~₹10-11M in 9 months).
medium · data_observationCurrency volatility in branded export markets
Promotional branded business is stable but can be impacted by currency fluctuations in emerging markets.
low · management_commentaryNotable Quotes
Our domestic business for Q3 FY26 has delivered a growth of around 12% for the quarter.
Our aim is to reach EBITDA margin to begin with around 15% maybe in 2-3 years time and gradually improve it to about 20%.
We have about 35 registrations out of which five we have commercialized. Another five to seven molecule will get commercialized over next 12 to 15 months.
Frequently Asked Questions
What was IPCA Laboratories's revenue in Q3 FY26?
IPCA Laboratories reported revenue of ₹2,245 Cr in Q3 FY26, representing a +6.5% change compared to the same quarter last year.
What guidance did IPCA Laboratories management give for FY27?
Revenue growth of 10-12% across segments: Management expects 10-12% growth in domestic, branded exports, and generic businesses; API slightly lower. Annual EBITDA margin expansion of ~150 bps: At 10-11% topline growth, EBITDA margin should improve by ~1.5% per year. Unichem to achieve 15% EBITDA margin in 2-3 years: Unichem aims for 15% EBITDA margin in 2-3 years, then gradually to 20% as European filings commercialize. 5-7 new US product launches from IPA portfolio in 12-15 months: IPA will commercialize 5-7 additional molecules in the US over next 12-15 months, adding to existing 5.
What are the key risks for IPCA Laboratories in FY27?
Key risks include Unichem US market share loss persists — Unichem lost market share in key US products; decline may continue for 1-2 more quarters, pressuring margins.; UK generic pricing pressure — UK generic market experienced severe price erosion; though recent recovery of 30-40% seen, sustainability uncertain.; Dependence on IKA portfolio for US growth — US growth largely driven by IKA portfolio; organic IPA US business still small (~₹10-11M in 9 months).; Currency volatility in branded export markets — Promotional branded business is stable but can be impacted by currency fluctuations in emerging markets..
Did IPCA Laboratories meet its previous quarter's guidance?
Scorecard data is being built as historical quarters are processed.
Where can I read the full IPCA Laboratories Q3 FY26 concall transcript?
The full earnings conference call transcript or source release is available on the linked source material. This page provides an AI-generated summary with filing verification status shown on the financial stats.